PRDX3

Across TCGA pan-cancer cohorts, PRDX3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PRDX3 data layer compared with 20 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PRDX3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PRDX3 expression acts as an unfavorable survival marker, although some lineages such as COAD and PDAC show a favorable association.

HNSC, COAD, and PDAC are the cancer types where PRDX3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Quartile	All	0.432	0.798	.005	30	view →
COAD	DFS	Median	All	1.000	0.885	.018	24	view →
PDAC	OS	Median	II,III,IV	0.601	0.394	.023	18	view →
CCRCC	DFS	Tertile	II,III,IV	0.959	0.157	.011	11	view →
LUAD	DFS	Tertile	III,IV	0.875	0.331	.011	7	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PRDX3–HNSC (DFS)

Open the HNSC breakdown →